Effect of Baohuoside-1 aglycone and tacrolimus monotherapy and combination therapy on prevention of acute heart allograft rejection in the rat.
Baohuoside-1 (B-1), a recently introduced novel immunosuppressant that was proved to be potent in inhibition of T and B cell proliferation and B-1, also prevents cardiac allograft rejection in rodents. The present study further proved that monotherapy of B-1's analogue B-1 aglycone effectively prolongs cardiac allograft survival and combination therapy of B-1 aglycone with tacrolimus (FK506) produces synergistic effect in prevention acute cardiac allograft rejection in the rat. .
Qi
Shijie
S
Laboratory of Experimental Surgery, Research Center of Centre Hospitalier de l'Université de Montréal, Hôspital Notre-Dame, Montreal, QC, Canada.
Zhao
Hong
H
Ma
Anlun
A
Liu
Longshan
L
Wang
Xiang
X
Xu
Dasheng
D
Lin
Geng
G
Tamura
Kouichi
K
Jiang
Hongsi
H
Daloze
Pierre
P
Chen
Huifang
H
D000208:Acute Disease; D000818:Animals; D004359:Drug Therapy, Combination; D005419:Flavonoids / Q000737:chemistry / Q000627:therapeutic use*; D006084:Graft Rejection / Q000517:prevention & control*; D016027:Heart Transplantation / Q000401:mortality*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D011897:Random Allocation; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D015996:Survival Rate; D016559:Tacrolimus / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D005419:Flavonoids; D007166:Immunosuppressive Agents; C060988:baohuoside I; D016559:Tacrolimus